Nordic Bio Investor portfolio performance

 

The NBI Investment Portfolio was launched March 25th, 2011. 

 

We publicly disclose the performance of the portfolio by the end of each quarter. Please note that only our clients have access to the specific stocks and their relative weigthting in the portfolio.

 

The NBI investment portfolio consists of public listed Nordic Life Sciences companies in Denmark, Finland, Norway and Sweden.

 

Accumulated return since portfolio inception 25 March 2011:

Performance listed as of 30 September 2014

 

NBI Investment Portfolio:  +145.6%

Primary Peer - Nordic Life Science Index: +25.9%

Secondary Peer - EuroNext Biotech Index: +34.9%

 

 

Annual performance for present and previous years:

 

2014 year to date (last update: 30 September 2014)

NBI Investment Portfolio: +25.0%

Primary Peer - Nordic Life Science Index: +9.1%

Secondary Peer - EuroNext Biotech Index: +40.1%

 

2013

NBI Investment Portfolio: +113.2%

Primary Peer - Nordic Life Science Index: +40.6%

Secondary Peer - EuroNext Biotech Index: -18.1%

 

2012

NBI Investment Portfolio: +3.9%

Primary Peer - Nordic Life Science Index: +7.8%

Secondary Peer - EuroNext Biotech Index: +67.5%

 

2011

NBI Investment Portfolio: -11.3%

Primary Peer - Nordic Life Science Index: -23.8%

Secondary Peer - EuroNext Biotech Index: -29.8%

 

 

 

Become a Client/Subscriber

 

For new Corporate Clients we are right now offering a free 6-week no commitment trial period which include 3 issues of NBI Insight.

 

For new Individual Clients we are offering a free 2-week no commitment trial period, which include 1 issue of NBI Insight. 

 

To sign up for a free trial period please fill in the requested information below:

Name        

Company 

E-mail      

Comments              

              

 

 

                                           Copyright NordicBioInvestor.com